Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose quadrivalent influenza vaccine dose-ranging study in children and adolescents
2018-005026-39Phase 2
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of quadrivalent influenza vaccine in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Number of participants reporting solicited injection site reactions or systemic reactions.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2018-005026-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-005026-39.